Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FluCide-HP
- Development stage
- Preclinical
- Lead developer
- NanoViricides
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
FluCide-HP is an investigational antiviral agent developed by NanoViricides, Inc., designed for the treatment of severe and highly pathogenic influenza infections, including H5N1 and H7N9. Utilizing the company's proprietary nanoviricide platform, the drug consists of polymeric micelles functionalized with specific ligands that mimic the sialic acid receptors on host cells. These ligands bind to the hemagglutinin (HA) protein on the surface of the influenza virus. Unlike traditional small-molecule antivirals that inhibit viral replication inside the cell, FluCide-HP acts extracellularly by "trapping" and neutralizing the virus particles, effectively dismantling the viral envelope and preventing cellular entry. This biomimetic approach is intended to provide broad-spectrum activity against various influenza strains and reduce the likelihood of resistance.
- Brand names
- FluCide-HP
- Other names
- FluCide
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on FluCide-HP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FluCide-HP.